Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine as adjunctive therapy for moderate to severe obsessive-compulsive disorder
IRCT201705191556N99Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of amantadine in obsessive compulsive disorder (OCD), sponsored by Tehran University of Medical Sciences. Started May 2017; status: completed.
02
Drugs
amantadine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT201705191556N99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201705191556N99.